BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

China advances commercialisation of long-acting COVID-19 neutralising antibody therapy

30 March 2022 | News

Brii Bio announces strategic partnership with Sinopharm for the commercialisation



Brii Biosciences has announced that TSB Therapeutics (Beijing), a joint venture majority-owned by the company, is partnering with Sinopharm Holding to advance stockpiling, channel distribution and regional access of the company's long-acting neutralising monoclonal antibody (mAb) therapy, the amubarvimab/romlusevimab combination, to help contribute to COVID-19 pandemic prevention and control efforts in China.

On December 8, 2021, the National Medical Products Administration (NMPA) of China approved the amubarvimab/romlusevimab combination (previously BRII-196/BRII-198 combination) for the treatment in adults and pediatric patients with mild and normal type of COVID-19 at high risk for progression to severe disease, including hospitalization or death.

On March 21, 2022, the National Healthcare Security Administration of China issued a notice to temporarily include the newly added drugs in the Guidelines in reimbursement by the provincial health insurance fund. Since March 22, 2022, the Healthcare Security Administrations of various provinces and cities, including Hunan, Beijing, Shanghai, Zhejiang, Jiangsu, Sichuan, Shanxi, Guizhou, Liaoning and Anhui, have successively implemented the instructions of the notice and included the amubarvimab/romlusevimab combination into the reimbursement of the local health insurance fund.

Brii Biosciences is rapidly preparing production and supply to provide the combination therapy to patients in need as soon as possible.